Skip to main content

Panelists discuss how selecting the appropriate treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) involves considering disease characteristics, patient preferences, and treatment response, with options ranging from intravenous immunoglobulin (IVIg) to emerging therapies based on individual needs and safety considerations.:

Source: Neurology Read More